SPRUCE BIOSCIENCES INC (SPRB)

Company Profile

Spruce Biosciences, Inc. operates as a late-stage biopharmaceutical company, which focuses on the development of novel therapies for rare diseases affecting the endocrine system. The company is headquartered in South San Francisco, California and currently employs 31 full-time employees. The company went IPO on 2020-10-09. The firm is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). The firm is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS) with adrenal dysfunction. The firm has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with highly elevated levels of androstenedione (A4) at baseline. The company has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction.

Company Info

SPRUCE BIOSCIENCES INC

611 Gateway Boulevard, Suite 740

South San Francisco CALIFORNIA 94104

P: 14156554168

CEO: Richard King

Employees: 31

Website: http://www.sprucebiosciences.com/